Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5151143 | 0.97 | TAAR1 (0.58) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| SCHEMBL537203 | 0.94 | TAAR1 (0.60) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| SCHEMBL14306680 | 0.85 | TAAR1 (0.54) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| SCHEMBL4213627 | 0.84 | TAAR1 (0.45) | TAAR1CYP2A6CYP1A2HTR2AALDH1A1 | |
| SCHEMBL17277598 | 0.84 | TAAR1 (0.50) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| SCHEMBL5045761 | 0.84 | TAAR1 (0.50) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| SCHEMBL6907499 | 0.84 | TAAR1 (0.50) | TAAR1CYP2A6CYP1A2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL5151086 | 0.82 | TAAR1 (0.43) | TAAR1CYP2A6CYP1A2ALDH1A1TSHR | |
| SCHEMBL15787310 | 0.82 | MAOA (0.48) | TAAR1CYP2A6CYP1A2HTR2AALDH1A1 | |
| SCHEMBL3690305 | 0.82 | ALDH1A1 (0.44) | TAAR1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163776-A | Epoxy resin with pressure-bearing and leakage-stopping functions and preparation method thereof | 西南石油大学 | 2022-03-11 | — | — | CN | claimed |
| CN-114163776-A | Epoxy resin with pressure-bearing and leakage-stopping functions and preparation method thereof | 西南石油大学 | 2022-03-11 | — | — | CN | disclosed |
| CN-102906079-B | Germination-stimulating carbamate derivatives and process for their preparation | NAT UNIV CORP UNIV KOBE | 2014-11-05 | — | — | CN | disclosed |
| CN-102906079-A | Germination-stimulating carbamate derivatives and process for their preparation | NAT UNIV CORP UNIV KOBE | 2013-01-30 | — | — | CN | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-5344830-A | Anitinflammatory, cardiovascular, analgesic, central nervous system | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| WO-1994013646-A1 | N,N-DIACYLPIPERAZINE TACHYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | TAAR1 173/4885CYP2A6 1120/4885CYP1A2 2499/4885 |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | NPSR1, SSTR2, PROKR1 | TAAR1 146/4885CYP2A6 2454/4885CYP1A2 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.